Thromb Haemost 1997; 77(05): 0834-0838
DOI: 10.1055/s-0038-1656063
Cinical Studies
Schattauer GmbH Stuttgart

Subcutaneous Recombinant Hirudin (HBW 023) Versus Intravenous Sodium Heparin in Treatment of Established Acute Deep Vein Thrombosis of the Legs: a Multicentre Prospective Dose-ranging Randomized Trial

François Schiele
1   The Hôpital Saint-Jacques, Besançon, France
,
Folke Lindgaerde
3   Malmö Almanna Syukhus, Malmö, Sweden
,
Henry Eriksson
4   Oestra Sjukhuset CK plan 2, Gothenburg, Sweden
,
Jean-Pierre Bassand
1   The Hôpital Saint-Jacques, Besançon, France
,
Anders Wallmark
3   Malmö Almanna Syukhus, Malmö, Sweden
,
Per-Olaf Hansson
4   Oestra Sjukhuset CK plan 2, Gothenburg, Sweden
,
Gilles Grollier
2   Hôpital de la Côte de Nacre, Caen, France
,
Malvin Sjo
5   Regionsykehuset I Tromsö, Norway
,
Marco Moia
6   Ospedale Maggiore, Milan, Italy
,
Anne Camez
7   Laboratoires Hoechst, Paris, France
,
Vince Smyth
8   Manchester Royal Infirmary, Manchester, Great Britain
,
for the International Multicentre Hirudin Study Group,
Michael Walker
8   Manchester Royal Infirmary, Manchester, Great Britain
› Author Affiliations
Further Information

Publication History

Received 25 July 1996

Accepted after resubmission 14 January 1997

Publication Date:
11 July 2018 (online)

Preview

Summary

The aim of this multicentre, prospective, randomised, dose-ranging study was to compare the safety and efficacy of subcutaneous recombinant hirudin (HBW 023) against intravenous sodium heparin in acute lower limb deep venous thrombosis (DVT). Patients were randomized to treatment with either HBW 023 or heparin for 5 ±1 days. HBW 023 was given according to body-weight in three dose groups. Thromboembolic disease was assessed by phlebography and ventilation/perfusion (V/Q) scanning on Bay 1 and Day 5±1. One hundred and fifty-five patients were enrolled, of these 121 were evaluable for efficacy analysis. Significantly fewer patients on HBW 023 developed new V/Q abnormalities during the treatment period, (p = 0.006). There was no difference between the groups in thrombus extension or regression, major bleeding complications or serious adverse events. There were significantly fewer findings of new V/Q mismatch after treatment with HBW 023, and anticoagulant control was superior in these patients.